IDM 2
Alternative Names: Bexidem; IDM-2Latest Information Update: 22 Feb 2010
At a glance
- Originator IDM Pharma
- Developer Takeda America Holdings
- Class Cell therapies; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bladder cancer
Most Recent Events
- 25 Jun 2009 IDM Pharma has been acquired and merged into Takeda America Holdings
- 25 Jun 2009 IDM Pharma has been acquired by Takeda America Holdings
- 13 Jun 2006 The US FDA has conducted a Special Protocol Assessment on the planned US phase II/III clinical trial for superficial bladder cancer